Iovance Biotherapeutics (IOVA) closed at $8.04 on November 6, 2026, up 3.9% from the previous close, on volume of 11,672,035 shares (30-day average 16,836,864).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts | Position |
|---|---|---|---|---|---|
| 1 | Oct 29, 2026 | Call Spread | 15-Jan-2710 : 17 C | 15,030 | |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | ||||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Iovance Earnings Call Signals Strong AMTAGVI Momentum
TipRanks (Thu, 5-Nov 7:11 PM ET)
Iovance Biotherapeutics Updates Corporate Presentation Highlighting TIL Platform
TipRanks (Thu, 5-Nov 6:26 PM ET)
TipRanks (Thu, 5-Nov 4:50 PM ET)
TipRanks (Thu, 5-Nov 2:00 PM ET)
Iovance posts ~$122M record quarter as Amtagvi demand lifts gross margin to ~60%
Market Chameleon (Thu, 5-Nov 2:19 AM ET)
Iovance Biotherapeutics GAAP EPS of -$0.05 beats by $0.04, revenue of $121.47M beats by $5.9M
Seeking Alpha News (Thu, 5-Nov 7:07 AM ET)
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Iovance Biotherapeutics Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 4-Nov 2:02 PM ET)
Iovance spotlights a 59.1% response-rate subgroup in metastatic non-squamous lung cancer trials
Market Chameleon (Thu, 29-Oct 3:08 AM ET)
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Iovance Biotherapeutics trades on the NASDAQ stock market under the symbol IOVA.
As of November 9, 2026, IOVA stock price climbed to $8.72 with 5,432,023 million shares trading.
IOVA has a beta of 1.29, meaning it tends to be more sensitive to market movements. IOVA has a correlation of 0.02 to the broad based SPY ETF.
IOVA has a market cap of $3.89 billion. This is considered a Mid Cap stock.
Last quarter Iovance Biotherapeutics reported $121 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.04.
In the last 3 years, IOVA traded as high as $18.33 and as low as $1.64.
The top ETF exchange traded funds that IOVA belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.
IOVA has outperformed the market in the last year with a return of +277.5%, while the SPY ETF gained +13.2%. In the last 3 month period, IOVA beat the market returning +40.4%, while SPY returned -2.0%. However, in the most recent 2 weeks IOVA has underperformed the stock market by returning -38.1%, while SPY returned -1.2%.
IOVA support price is $7.56 and resistance is $8.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IOVA shares will trade within this expected range on the day.
